Confirmed First-Line Standard for EGFR-Mutant NSCLC
Adding chemotherapy to first-line treatment with osimertinib improves overall survival in patients with EGFR-mutant, advanced non-small cell lung cancer (NSCLC), according to the FLAURA2 trial.
“These compelling overall survival results from the FLAURA2 trial confirm osimertinib plus chemotherapy as the first-line standard of care in EGFR- advanced non-small cell lung cancer,” said study presenter David Planchard, MD, PhD.
The phase 3 trial included 557 adults with previously untreated, EGFR-mutant, locally advanced/metastatic NSCLC, who were randomly assigned to receive osimertinib plus chemotherapy or osimertinib alone.
- 279 patients received osimertinib plus chemotherapy
- 278 patients received osimertinib alone
Author's summary: Osimertinib plus chemo is a new standard for EGFR-mutant NSCLC.
More News
- Interview: Haitian American vocalist blends Afrobeats and Caribbean music styles
- Demon Slayer's Box Office Success Is Going to Be Trouble for Its Future
- 20 Things To Do in Grapevine for the Perfect Texas Getaway
- We should all find a way to express our gratitude
- How Computer-Aided Design Changed the World - CEOWORLD magazine
- 7 Great Dark Anime Nobody Talks About
- Are Twiggy Forrest’s green goals uneconomic or has China bounced him? - Switzer Daily
- DA outraged by brutal Mpumalanga farm attack
- Slideshow: Bethel comes together to celebrate Indigenous Peoples' Day
- Trump administration revokes visas for 6 foreigners over Charlie Kirk-related speech